Comparative Pharmacology
Head-to-head clinical analysis: ACCUPRIL versus CAPOZIDE 25 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACCUPRIL versus CAPOZIDE 25 25.
ACCUPRIL vs CAPOZIDE 25/25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiotensin-converting enzyme (ACE) inhibitor; inhibits ACE, thereby blocking conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure.
Captopril: angiotensin-converting enzyme (ACE) inhibitor that blocks conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide: thiazide diuretic that inhibits sodium-chloride symporter in distal convoluted tubule, increasing sodium, chloride, and water excretion.
10-40 mg orally once daily; initial dose 10 mg, titrate to target dose based on blood pressure response; maximum 80 mg/day.
1 tablet (captopril 25 mg / hydrochlorothiazide 25 mg) orally once daily initially; may titrate up to 2 tablets per day as needed.
None Documented
None Documented
Quinaprilat terminal elimination half-life is approximately 3 hours. In patients with renal impairment (CrCl <30 mL/min), half-life can be prolonged up to 10-25 hours, requiring dose adjustment.
Captopril: ~2 hours (increased in renal impairment). Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment). Clinical context: trough effect may diminish with once-daily dosing; twice-daily dosing often used.
Primarily renal (about 60% as unchanged drug and 40% as metabolites, mainly quinaprilat), with biliary/fecal elimination accounting for less than 10%.
Captopril: renal 95% (40-50% unchanged), biliary/fecal <5%. Hydrochlorothiazide: renal >95% (unchanged), biliary/fecal minimal.
Category C
Category C
ACE Inhibitor
ACE Inhibitor and Diuretic Combination